AstraZeneca Has Dazzled in Recent Cancer Trials, but Faces Stiff Competition

AstraZeneca recently reported positive interim data from clinical trials of two, and potentially a third, of its drugs for cancer. As promising as that data looks, they will face an increasingly complicated and competitive market for both checkpoint inhibitors and BTK inhibitors. Here’s a look.